Liquidia plans PH-ILD enrollment completion in 2028 with L606 NDA submission target in 2029
At a glance
- $LQDA today−0.12%last $56.30
- Vs industry peers+1.08 pts6-peer median −1.20% · ahead
- Since Nov 10+11.5%from the first trade after the story
- 52-week range152.4% above low$22.31 – $93.61
- Last reported loss$236.3Mquarter to Sep 30, 2026 · 10-Q
- Coverage1 this week3 in 30 days · too few stories to call a pace
Nothing reported about liquidia across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Drugmakers thrive on progress — late-stage trials are the real game, not quarterly earnings.
- How the stock is trading: $LQDA -0.12% in the latest session.
- Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Where the stock stands
Liquidia ($LQDA) slipped 0.12% to $56.30 in the latest session. Over the past month it is up 66.2%. That leaves it 40% below its 52-week high of $93.61 and 152% above its low of $22.31. It has been a volatile year: the high was 4.2 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $LQDA lost $236.3M over the quarter to Sep 30, 2026 on revenue of $225.3M (+31.2% QoQ). Operations brought in $279.9M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $248.9M. Total liabilities were $708.4M against $396.1M of cash on Sep 30, 2026. Liabilities of $708.4M exceeded assets of $682.9M on Sep 30, 2026, leaving book equity negative. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $LQDA's own account and the first thing to read. Figures are as filed with the SEC; the $LQDA page has the full statements.
How much coverage it is getting
Wook has filed 3 stories on Liquidia in the last 30 days, 1 of them this week. That is a little busier than usual: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 3 neutral and 0 bearish. This one reads neutral too, in line with most of them. Seeking Alpha wrote 2 of the 3 (67%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, timing is everything — trial results, FDA rulings, and pricing shifts can turn a drugmaker's fate in an instant. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The $LQDA page has all the charts, filings, and models. One outlet dominates the story, so checking another is key to seeing if it's confirmed or just echoed. Wook AI can fetch live data and crunch the numbers — how far $LQDA is from its peak, or how this week's coverage stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 10, 2026. $LQDA has moved +11.49% ($50.50 to $56.30). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
